This company listing is no longer active

This company may still be operating, however this listing is no longer active. Find out why through their latest events.

Bionomics Balans Gezondheid

Financiële gezondheid criteriumcontroles 6/6

Bionomics heeft een totaal eigen vermogen van A$47.7M en een totale schuld van A$0.0, wat de schuld-eigenvermogensverhouding op 0% brengt. De totale activa en totale passiva bedragen respectievelijk A$56.3M en A$8.6M.

Belangrijke informatie

Verhouding schuld/eigen vermogen

AU$0

Schuld

Rente dekkingsratio	n/a
Contant	AU$30.70m
Aandelen	AU$47.72m
Totaal verplichtingen	AU$8.59m
Totaal activa	AU$56.31m

Recente financiële gezondheidsupdates

Recent updates

Is Bionomics (ASX:BNO) In A Good Position To Deliver On Growth Plans?

Jun 14

Is Bionomics (ASX:BNO) In A Good Position To Invest In Growth?

Feb 23

Is Bionomics (ASX:BNO) In A Good Position To Deliver On Growth Plans?

Sep 14

Companies Like Bionomics (ASX:BNO) Are In A Position To Invest In Growth

Nov 15

Did You Miss Bionomics' (ASX:BNO) 86% Share Price Gain?

Dec 30

Analyse van de financiële positie

Kortlopende schulden: De korte termijn activa ( A$33.1M ) BNO } overtreffen de korte termijn passiva ( A$3.7M ).

Langlopende schulden: De kortetermijnactiva BNO ( A$33.1M ) overtreffen de langetermijnschulden ( A$4.9M ).

Schuld/ eigen vermogen geschiedenis en analyse

Schuldniveau: BNO is schuldenvrij.

Schuld verminderen: BNO heeft geen schulden vergeleken met 5 jaar geleden, toen de schuld/eigen vermogen-ratio 63.9% was.

Balans

Analyse van de cashflow

Voor bedrijven die in het verleden gemiddeld verliesgevend zijn geweest, beoordelen we of ze ten minste 1 jaar kasstroom hebben.

Stabiele cash runway: BNO heeft op basis van de huidige vrije kasstroom voldoende kasstroom voor meer dan een jaar.

Voorspelling contante baan: BNO heeft voldoende kasruimte voor 1.7 jaar als de vrije kasstroom blijft dalen met een historisch percentage van 9 % per jaar.

This company listing is no longer active

Bionomics Balans Gezondheid

Financiële gezondheid criteriumcontroles 6/6

Belangrijke informatie

Recente financiële gezondheidsupdates

Is Bionomics (ASX:BNO) In A Good Position To Deliver On Growth Plans?

Is Bionomics (ASX:BNO) In A Good Position To Invest In Growth?

Is Bionomics (ASX:BNO) In A Good Position To Deliver On Growth Plans?

Companies Like Bionomics (ASX:BNO) Are In A Position To Invest In Growth

Recent updates

New minor risk - Financial data availability

Bionomics Completes Last Patient Last Visit in the Phase 2B Attune Study for Post-Traumatic Stress Disorder

New major risk - Market cap size

Bionomics Limited Appoints Tim Cunningham as Chief Financial Officer

Is Bionomics (ASX:BNO) In A Good Position To Deliver On Growth Plans?

First half 2023 earnings released: AU$0.012 loss per share (vs AU$0.013 loss in 1H 2022)

Is Bionomics (ASX:BNO) In A Good Position To Invest In Growth?

High number of new directors

Bionomics Limited Reports Results in PREVAIL Phase2 Study BNC210

High number of new and inexperienced directors

Bionomics Limited, Annual General Meeting, Nov 16, 2022

Is Bionomics (ASX:BNO) In A Good Position To Deliver On Growth Plans?

Full year 2022 earnings: EPS and revenues exceed analyst expectations

High number of new and inexperienced directors

High number of new and inexperienced directors

Bionomics Limited announced that it has received $2.794495 million in funding

Bionomics Initiates Phase 2 Prevail Study of Bnc210 for the Acute Treatment of Social Anxiety Disorder

High number of new directors

U.S. Food and Drug Administration Grants Bionomics Fast Track Designation to Bnc210 for the Acute Treatment of Social Anxiety Disorder and Other Anxiety Related Disorders

Companies Like Bionomics (ASX:BNO) Are In A Position To Invest In Growth

Bionomics Prepares BNC210 for Start of Phase 2 Acute Treatment of Social Anxiety Disorder Trial

Full year 2021 earnings released: AU$0.01 loss per share (vs AU$0.011 loss in FY 2020)

Bionomics Initiates Phase 2B ATTUNE Study of BNC210 in PTSD

Bionomics BNC210 Expansion into Social Anxiety Disorder

Legal Counsel & Company Secretary has left the company

Bionomics Limited has completed a Follow-on Equity Offering in the amount of AUD 15.991634 million.

New 90-day high: AU$0.39

Bionomics Limited Announces Positive BNC210 PK Results for Solid Dose Formulation

Bionomics Limited and EmpathBio Inc Joint Feasibility Assessment

Bionomics Limited announced that it expects to receive AUD 15.991634 million in funding

New 90-day high: AU$0.22

Bionomics Limited Completes Treatment Phase in the MODULATE Clinical Trial

Bionomics Limited Announces Publication of Positive BNC210 Phase 2a Data in Gad Patients

Bionomics Limited Initiates 7-Day Dosing Pharmacokinetic Study of BNC210

Did You Miss Bionomics' (ASX:BNO) 86% Share Price Gain?

Bionomics Limited Licenses Drug Candidate BNC101 to Carina Biotech

Bionomics Limited Announces Director Changes

Bionomics Limited announced that it has received AUD 5.43332 million in funding from Apeiron Investment Group Ltd. and other investors

Full year earnings released - AU$0.0082 loss per share

Analyse van de financiële positie

Schuld/ eigen vermogen geschiedenis en analyse

Balans

Analyse van de cashflow

Ontdek gezonde bedrijven